DOC-2/hDab-2 was identi®ed due to the loss of its expression in primary ovarian cancer cells. It is believed that loss of DOC-2/hDab-2 expression is one of the early events of ovarian malignancy. These results suggest a function of DOC-2/hDab-2 as a tumor suppressor. However, it is not clear how DOC-2/hDab-2 negatively regulates cancer cell growth. In this report, we demonstrate that DOC-2/hDab-2 expression in breast cancer cells resulted in sensitivity to suspension-induced cell death (anoikis). This event was associated with the down-regulation of the integrin-linked kinase (ILK) activity. Since ILK is a key factor in regulating the cellular signaling in responding to the extracellular signals through adhesion molecules like integrins, our results indicate that DOC-2/hDab-2 may prevent tumor growth and invasion by modulating the anti-apoptotic ILK pathway. Oncogene (2001) 20, 6960 ± 6964.
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Keywords: ILK; DOC-2/hDab-2; anoikis; breast cancer; HER-2; neu The human DOC-2/hDab-2 gene (dierentially-expressed in ovarian carcinoma-2/human disabled-2) was originally isolated based on a dierential RNA ®ngerprint screening of normal versus cancer epithelial ovarian cells (Fazili et al., 1999; Mok et al., 1994 Mok et al., , 1998 Xu et al., 1995 Xu et al., , 1998 . Expression of the DOC-2/hDab-2 gene is mitigated or lost in multiple ovarian cancer cell lines as well as in tissues derived from serous ovarian tumors when compared with the expression levels in normal ovarian cells (Mok et al., 1994 (Mok et al., , 1998 . The DOC-2/hDab-2 protein contains a phosphotyrosine interacting domain (PID) at the N terminal region and multiple proline-rich SH3 binding motifs at the C terminus (Mok et al., 1998) . These motifs are also conserved in the mouse homologue of DOC-2/ hDab-2, p96/mDab2, suggesting critical biological functions associated with these motifs (Xu et al., 1995 (Xu et al., , 1998 . The SH3 binding motifs of the mouse p96/mDab2 protein have been shown to interact with the SH3 domains of Grb2 and reduce the binding between Grb2 and Sos (Xu et al., 1998) . The observations suggest that DOC-2/hDab-2 may be involved in the signaling pathway mediated by tyrosine phosphorylations.
In normal tissues, DOC-2/hDab-2 expression is distributed in the surface epithelial cells of ovary or the ductal epithelial cells of breast (Fazili et al., 1999; Mok et al., 1994 Mok et al., , 1998 Sheng et al., 2000) . Loss of DOC-2/hDab-2 expression in ovarian cancer appears to be an early tumorigenesis event in serous but not mucinous ovarian cancer (Fazili et al., 1999; Mok et al., 1998) . It has been reported that DOC-2/hDab-2 expression is correlated with the presence of basement membrane in ovarian and breast tumors, suggesting that DOC-2/hDab-2 exerts its anti-tumor function by controlling the positioning of the epithelial cells to basement membrane (Sheng et al., 2000) . Consistently, reconstitution of DOC-2/hDab-2 expression in human ovarian cancer cells resulted in reduction of growth rate in culture and tumorigenicity in nude mice (Mok et al., 1998) . However, the mechanism of the tumor suppression function of DOC-2/hDab-2 remains unclear.
To further explore the function of DOC-2/hDab-2, we constructed a recombinant adenovirus of DOC-2/ hDab-2. Infection of two breast cancer cell lines, SK-BR-3 and MDA-MB-453, showed a dose-dependent manner of adenovirus-mediated DOC-2/hDab-2 expression (Figure 1 ). Both cell lines express low or undetectable levels of endogenous DOC-2/hDab-2 protein. Even though¯ow cytometry analysis indicated that DOC-2/hDab-2 expression did not signi®cantly aect the proliferation of these cell lines in attached cell culture (data not shown), ectopic Figure 2c ). By using¯ow cytometry, consistently higher apoptotic frequency in cells infected with Ad.DOC-2/hDab-2 was also detected (data not shown). Due to the nature of the experimental condition, background apoptotic cells can be observed in both groups for both TUNEL and¯ow cytometry (Figure 2 ; data not shown).
Under our experimental condition, DOC-2/hDab-2 expression did not alter the activation of the ERK signaling pathway, nor the JNK stress responsive pathway (Figure 3a,b) . Since both SK-BR-3 and MDA-MB-453 cells express high level of the tyrosine kinase receptor HER-2/neu, and that HER-2/neu overexpression has been reported to enhance cell survival in anchorage-independent growth (Yu and Hung, 1991), we next checked the protein levels and the tyrosine phosphorylation status of HER-2/neu in these cell lines. DOC-2/hDab-2 expression apparently had no eect on either protein expression or the autophosphorylation status of HER-2/neu ( Figure  3a,b) . Similarly, DOC-2/hDab-2 has no eect on the activity of the anti-apoptotic protein kinase B/Akt (Figure 3c) .
The induced apoptosis in detached cells by DOC-2/ hDab-2 suggests that DOC-2/hDab-2 may block the anti-apoptotic arm downstream the integrin signaling pathway. The major survival determinant in the integrin pathway is the integrin-linked kinase (ILK) (Dedhar, 2000) . ILK is a serine/threonine kinase and plays a critical role for cell proliferation, survival, and tumor development (Dedhar, 2000; Persad et al., 2000) . ILK interacts with the cytoplasmic domain of integrin b1 and b3 and can be stimulated by extracellular matrix attachment. ILK can also be activated by growth factor stimulation in a PI-3 kinase-dependent manner (Delcommenne et al., 1998) . Overexpression of ILK in breast cancer cells confers resistance to anoikis, while down-regulation of ILK in breast cancer cells sensitized the cells to anoikis . Since SK-BR-3 and MDA-MB-453 cells express high levels of ILK (Makino, unpublished results), we tested the possible involvement of ILK in the DOC-2/hDab-2 signaling pathway by examining the kinase activity of ILK in cells overexpressing DOC-2/hDab-2 (Figure 4 ). DOC-2/ hDab-2 expression resulted in signi®cant down-regulation of ILK activity in SK-BR-3 and MDA-MB-453 cells and the level of down-regulation was closely correlated to the induction levels of anoikis as evaluated by TUNEL assay mentioned above ( Figure  2) .
We have demonstrated that the putative tumor suppressor gene DOC-2/hDab-2 sensitizes breast cancer cells to apoptosis induced by loss of attachment to extracellular matrix. This event was accompanied by enzymatic down-regulation of the ILK kinase, a key anti-apoptotic mediator in processing signals stimulated by changes in the extracellular environment. Our study indicates that DOC-2/hDab-2 suppresses the development of breast cancer by targeting the oncogenic activity of ILK. These results also suggest a link between the DOC-2/hDab-2 function and the integrin-mediated signaling for cell survival. It is also possible that the tumor suppression function of DOC-2/hDab-2 is associated with its previously reported ability to interrupt the Grb2-Sos signaling cascade remains to be explored (Xu et al., 1998) . With this regard, it is noteworthy that the Shc2-Grb2-Sos signaling pathway has been shown to be involved in the activation of PI-3 kinase activity (Gu et al., 2000) , and that activation of PI-3 kinase results in the activation of a number of downstream regulators including ILK Oncogene DOC-2/hDab-2 inhibits ILK activity and induces anoikis S-C Wang et al (Dedhar, 2000; Delcommenne et al., 1998) . However, since DOC-2/hDab-2 expression does not result in any eect on the activity of Akt (Figure 3c ), a major downstream signaling factor of PI-3 kinase (Toker and Cantley, 1997) , it is unlikely that DOC-2/hDab-2 can directly inhibit PI-3 kinase activity itself. Similarly, DOC-2/hDab-2 appeared not to aect the activity of MAP kinases such as Erks and JNK in our system. It has been reported that DOC-2/hDab-2 expression inhibited the induction of c-fos and Erk1/2 (Sheng et al., 2000; Zhou and Hsieh, 2001 ). Both works elegantly showed that DOC-2/hDab-2 expression by adenovirus infection of transient transfection resulted in a transient inhibition of activation of c-fos and Erk1/2 phosphorylation induced by supplemented serum or EGF following serum starvation. The discrepancy between these reports and our study is likely due to the dierent experimental conditions. In our study, the eects of DOC-2/hDab-2 expression were observed in a constitutive manner without repression-activation treatment. DOC-2/hDab-2 may also modulate the activity of ILK by directly inhibiting the cross talk between integrins and ILK. While these possibilities remain to be tested, we show here that DOC-2/hDab-2 inhibited ILK activity and induced anoikis under a condition in which the PI-3 kinase/ Akt and MAP kinase pathways were not aected. Therefore, in addition to the anti-proliferation mechanisms as reported previously by others, we have identi®ed a novel mechanism of DOC-2/hDab-2 to induce cell death upon the loss of cell-matrix attachment. Elucidation of the dierent signaling mechanisms of DOC-2/hDab-2 will be critical to the understanding of pathogenesis and the development of a potential therapy for ovarian and breast cancer. Luc for 36 h in the absence of serum, cell lysates were prepared in the immunoprecipitation buer (0.5% NP-40, 150 mM NaC1, 50 mM Tris (pH 8.0), 2% aprotinin, 5 mM PMSF, 100 mM NaF, 2 mM Na 3 VO 4 , 1 mM EDTA). Five hundred micrograms of protein from each sample was incubated at 48C with 1 mg of anti-ILK antibody or normal rabbit IgG overnight and for another 2 h after addition of protein A-agarose. The immunoprecipitates were washed three times with IP buer and twice with kinase buer (20 mM HEPES (pH 7.4), 150 mM KC1, 5 mM MnC1 2 , 5 mM NaF, 1 mM DTT) and then resuspended in 40 ml of kinase buer containing 5 mg of myelin basic protein and 10 mCi of [g-32 P]ATP. Following 30 min incubations at 308C, the reactions were terminated with 40 ml of 26Laemmli SDS sample buer. Samples were incubated for 5 min at 968C, resolved by 15% SDS ± PAGE, and visualized by autoradiography. (b) The data were quanti®ed by ImageQuant software of a Phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA). The fold reduction of ILK kinase activity by DOC-2/hDab-2 expression is shown. (c) The expression and immunoprecipitation of DOC-2/ hDab-2 and ILK were con®rmed by a Western analysis following immunoprecipitation by anti-ILK, anti-DOC-2, or control IgG antibodies
